Halozyme Therapeutics Inc
$ 70.36
-0.40%
24 Feb - close price
- Market Cap 8,303,676,000 USD
- Current Price $ 70.36
- High / Low $ 71.39 / 70.15
- Stock P/E 27.48
- Book Value 0.41
- EPS 2.56
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.22 %
- ROE 1.54 %
- 52 Week High 82.22
- 52 Week Low 47.50
About
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Analyst Target Price
$84.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-28 | 2025-08-05 | 2025-05-06 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-06 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.24 | 1.72 | 1.54 | 1.11 | 1.26 | 1.27 | 0.91 | 0.79 | 0.82 | 0.75 | 0.74 | 0.47 |
| Estimated EPS | 1.9 | 1.61 | 1.23 | 0.94 | 1.1588 | 0.98 | 0.76 | 0.7 | 0.83 | 0.71 | 0.63 | 0.48 |
| Surprise | -2.14 | 0.11 | 0.31 | 0.17 | 0.1012 | 0.29 | 0.15 | 0.09 | -0.01 | 0.04 | 0.11 | -0.01 |
| Surprise Percentage | -112.6316% | 6.8323% | 25.2033% | 18.0851% | 8.7332% | 29.5918% | 19.7368% | 12.8571% | -1.2048% | 5.6338% | 17.4603% | -2.0833% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.76 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HALO
2026-02-23 12:17:07
Halozyme Therapeutics reported a quarterly net loss due to a major impairment charge, but plans to pursue acquisitions to expand its drug delivery portfolio. Despite recent stock volatility, the company has shown strong annual and five-year returns, and Simply Wall St assesses it as significantly undervalued compared to analyst targets and its estimated fair value. Investors are advised to monitor the impact of acquisitions on earnings, debt, and profit margins.
2026-02-23 12:03:03
Halozyme Therapeutics reported a net quarterly loss due to a major impairment charge but plans to pursue acquisitions to expand its drug delivery portfolio, despite strong revenue growth. The company's stock has seen mixed performance, with a recent dip but significant long-term gains, trading well below analyst targets and Simply Wall St's fair value estimate. Investors are advised to monitor its acquisition strategy, potential future impairments, and effects on its financial health.
2026-02-21 07:35:09
Halozyme Therapeutics (NASDAQ:HALO) has been downgraded from a "strong-buy" to a "hold" rating by Wall Street Zen. This follows Halozyme's recent earnings report where it missed EPS consensus but slightly exceeded revenue expectations. Despite the downgrade, the company still holds a "Moderate Buy" consensus rating from analysts with an average price target of $78.56.
2026-02-20 13:34:32
Jupiter Asset Management Ltd. increased its holdings in Halozyme Therapeutics (NASDAQ:HALO) by 19.4%, now owning 800,583 shares valued at approximately $58.7 million. This move comes despite recent insider selling by the company's director and CEO, totaling over $3.6 million in the last three months. Halozyme also reported a mixed earnings quarter, missing EPS estimates but exceeding revenue expectations with a 51.6% year-over-year increase, while analysts maintain a "Moderate Buy" rating with a $78.56 consensus price target.
2026-02-20 12:34:32
Halozyme Therapeutics reported significant growth in 2025, driven by accelerating royalty revenue from ENHANZE-enabled products, portfolio expansion into new subcutaneous drug delivery technologies, and new collaborations. The company achieved record revenue growth of 38% to $1.4 billion and expects to sign at least three new licensing agreements in 2026. Halozyme's ENHANZE technology improves patient access and convenience by enabling subcutaneous administration of biologic therapies.
2026-02-19 20:27:05
Halozyme Therapeutics, a San Diego-based biopharmaceutical company, reported a Q4 loss of $141.6 million, or $1.20 per share, missing analyst expectations. However, the company exceeded revenue forecasts with $451.8 million in the period. For the full year, Halozyme reported profits of $316.9 million and expects 2026 full-year earnings between $7.75 to $8.25 per share and revenue from $1.71 billion to $1.81 billion.
